Business Description
ASLAN Pharmaceuticals Ltd
ISIN : US04522R2004
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.69 | |||||
Equity-to-Asset | -0.86 | |||||
Debt-to-Equity | -1.48 | |||||
Debt-to-EBITDA | -0.86 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -26.3 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6.1 | |||||
3-Year EPS without NRI Growth Rate | -12.4 | |||||
3-Year FCF Growth Rate | -13.1 | |||||
3-Year Book Growth Rate | 15.4 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
12-1 Month Momentum % | 13.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.94 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28 | |||||
Shareholder Yield % | 278.65 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -290.42 | |||||
Net Margin % | -291.88 | |||||
FCF Margin % | -386.22 | |||||
ROA % | -85.11 | |||||
ROIC % | -335.91 | |||||
3-Year ROIIC % | 1363.46 | |||||
ROC (Joel Greenblatt) % | -3574.41 | |||||
ROCE % | -148.27 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.1 | |||||
EV-to-EBIT | -0.32 | |||||
EV-to-EBITDA | -0.32 | |||||
EV-to-Revenue | 0.83 | |||||
EV-to-Forward-Revenue | -128.7 | |||||
EV-to-FCF | -0.21 | |||||
Earnings Yield (Greenblatt) % | -312.5 | |||||
FCF Yield % | -2748.97 |